drugset / Trial / NCT03109730
Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B
RandomizedSequentialTriple-blindTreatment
Summary
The purpose of this protocol is to obtain pharmacodynamic and pharmacokinetic data on ABI-H0731 and to provide the opportunity for preliminary evaluation of combination therapy of ABI-H0731 with currently approved antiviral treatment for chronic hepatitis B.
Timeline
- Start
- 2017-06-15
- Primary completion
- 2018-03-31
- Completion
- 2018-06-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vebicorvir | Small molecule | — | Oral |
| Background | Entecavir | Small molecule | — | — |
| Background | Peginterferon alfa-2a | Protein / enzyme biologic | — | — |
| Background | Tenofovir disoproxil fumarate | Small molecule | — | — |